Universal anti-CD70 CAR-T (CHT101)

Phase 1Cell therapy

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Universal anti-CD70 CAR-T (CHT101) is one of 43 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Systemic Lupus Erythematosus (SLE)Recruiting

Systemic Lupus ErythematosusPhase 1

Active, not recruiting

Systemic Lupus Erythematosus (SLE)Phase 1

Recruiting

Competition

Competitive Landscape

328 competitors in Systemic Lupus Erythematosus

#DrugCompanyPhaseTrials

Eptanemab

UCB

Phase 3

12 2

Medrol

Pfizer

Phase 3

5 3

Olumiant

Eli Lilly

Phase 3

4 4

Gazyva

Roche

Phase 3

2 5

Cytoxan

BBaxter Healthcare Corporation

Phase 3

11 6

Intrarosa

Alnylam Pharmaceuticals

Phase 3

1 7

Cellcept

Benadryl

3 9

Sotyktu

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

2 10

Tylenol

KKenvue Brands

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Systemic Lupus Erythematosus (SLE)

NCT06946485

Clinical

Trials by Indication[1]

Systemic Lupus Erythematosus (SLE)1 trial

A Clinical Study of the Safety and Efficacy of Universal Anti-CD70 CAR-T (CHT101) for the Treatment of Relapsed and Refractory Systemic Lupus Erythematosus

Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 1·NCT06946485·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Universal anti-CD70 CAR-T (CHT101). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Universal anti-CD70 CAR-T (CHT101) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Universal anti-CD70 CAR-T (CHT101). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Universal anti-CD70 CAR-T (CHT101)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Systemic Lupus Erythematosus (SLE)1 trial

References

Drug Info

Quick Facts

Related News